A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

Top Cited Papers
Open Access
Abstract
The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the same trial.

This publication has 26 references indexed in Scilit: